Pazopanib
Drug Details
- Description
- Pazopanib is an oral multi-targeted tyrosine kinase inhibitor that interferes with tumor growth and angiogenesis by inhibiting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and KIT. It is primarily used in the treatment of renal cell carcinoma and soft tissue sarcoma.
- Alternative Names
- Pazopanib.
- Key Genes
- Key genes associated with Pazopanib include VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), PDGFR-α (PDGFRA), PDGFR-β (PDGFRB), and c-KIT (KIT).
- Drug Use
- Pazopanib is used to treat advanced renal cell carcinoma and soft tissue sarcoma in patients who have received prior chemotherapy.
- Genetic Factors Influencing Response
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Purchase Membership to Access Your Individual Drug Response Report